Viral Kansara, PhD

Evaluator
DISC Type : sdc

Vice President, Discovery & Development, Ophthalmology, at Clearside Biomedical, Inc.

Alpharetta, Georgia, United States

Overview

Viral Kansara is the VP of Development at Clearside Biomedical, where he leverages over 17 years of experience transforming molecules into approved medicines. He specializes in ophthalmic drug discovery and has led numerous programs through all stages of development. Colleagues describe him as brilliant, patient, collaborative, and proficient, highlighting his strength in team leadership and clear communication.

There is no publicly available information regarding Virals personal life or hobbies.

He played a key role in the FDA approval of XIPERE, the first commercial therapy delivered via the suprachoroidal space, a significant innovation in treating eye diseases.

Personality Overview

Thorough Evaluator

Hard To Convince

Fast But Analytical

They have a unique set of diverse traits where they are decisive and methodical but can sometimes be extra cautious and skeptical  They focus on the results, but can still be quite procedural and analytical about how to get there They are not very likely to become strong advocates of your product or service

Topics They Care About

Suprachoroidal Delivery
A primary focus of his work at Clearside Biomedical, he has authored multiple publications and given presentations on this innovative drug delivery platform for ocular diseases.
AI in Drug Discovery
He recently shared his perspective on how AI and computational tools can be integrated with biological insight to unlock the next generation of retinal drug therapies.
Translational Medicine
He emphasizes the critical importance of the translational phase, believing this is where the most significant breakthroughs in drug development are won.

Media Appearances

Clearside Biomedical Appoints Viral Kansara as Vice President, Discovery. Featured in Clearside Biomedical, Inc. – Investor Relations

See Now

PowerPoint Presentation – Gene Therapy at ARVO 2019 (by Viral Kansara, PhD). Featured in Clearside Biomedical, Inc.

See Now

Viral Kansara, PhD – Management Profile. Featured in Clearside Biomedical, Inc. – Investor Relations

See Now

Work History

9-2018
Vice President, Discovery & Development, Ophthalmology, at Clearside Biomedical, Inc.
10-2016 - 9-2018
Global Team Lead Ophthalmology & Head of Pharmacology Laboratory at Novartis Institutes for BioMedical Research (NIBR)
3-2014 - 10-2016
Head of Ocular Pharmacology Laboratory at Novartis Institutes for BioMedical Research (NIBR)
12-2010 - 2-2014
Head of Ocular Pharmacokinetics and Drug Delivery Laboratory at Novartis Institutes for BioMedical Research (NIBR)
7-2007 - 11-2010
Senior Research Chemist/BioPharmaceutics, Pharma. Sci. and RNAi at Merck

Education

2016 - 2016
Biomedical Drug Development from Harvard Extension School
2002 - 2007
Ph. D. from University of Missouri-Kansas City

More Information

Social Presence :

Prographics :

Exp : 19 Location : Alpharetta, Georgia, United States Job Level : Senior Designation : Vice President, Discovery & Development, Ophthalmology, at Clearside Biomedical, Inc.
URL has been copied!

Insights For Selling To Viral

During A Call Or A Meeting

DO's

  • Help them see both - the ‘big picture’ impact and the ROI of the investment
  • Help them weigh the risks by sharing objective proof points instead of anecdotes and examples
  • Showcase how you can impact results but also make sure that you share detailed information too

DONT's

  • Avoid self-deprecating references or general informality, it could decrease their trust in you
  • Avoid making strong statements, instead invite them to agree with you by asking them questions
  • Avoid inviting them for any social interactions until you have built some rapport with them

When Cold Calling

When Writing An Email

While Negotiating & Closing

    The secret to closing fast with Viral is

  • ROI matters the most to them, followed by process and finally proof of results
  • Will you ever get a clear answer from Viral

  • They might hesitate a little, but will go ahead and say no when necessary (or asked)

Insights For Deal Planning

    How fast (or slow) will Viral move?

  • They are unlikely to move very fast, especially when it comes to new products or services
  • Can Viral take some risk or not?

  • They have relatively low risk-appetite and are not very likely to go for something unproven and risky

You And Viral

Personality Compatibility


More Profiles

Discover additional public profiles from our index.

Search more profiles

Looking for someone else? Search here for anyone.

Or visit Humantic AI to know more.